Adverse Outcomes Increased With Long-Term Inhaled Corticosteroids in COPD
By Elana Gotkine HealthDay Reporter
FRIDAY, March 28, 2025 -- For patients with chronic obstructive pulmonary disorder (COPD), long-term inhaled corticosteroid (ICS) treatment is associated with increased rates of adverse composite and specific individual outcomes, according to a study published in the March/April issue of the Annals of Family Medicine.
Wilson D. Pace, M.D., from DARTNet Institute in Aurora, Colorado, and colleagues examined electronic health record data for individuals older than 45 years with COPD to assess long-term ICS risks. The prevalent cohort had a COPD diagnosis any time during the observation period (318,385 individuals), and the inception cohort had a COPD diagnosis after entry into the database (209,062 individuals). A composite outcome of any new diagnosis of type 2 diabetes, cataracts, pneumonia, osteoporosis, or nontraumatic fracture and recurrent event outcomes of repeated pneumonia or nontraumatic fracture were compared for long- versus short-term ICS exposure (>24 months versus <4 months).
The researchers found that the composite dichotomous outcome was significantly greater for long- versus short-term ICS use for both the prevalent and inception cohorts (hazard ratios, 2.65 and 2.60, respectively). The absolute risk difference of the composite outcome was 20.26 percent for the inception cohort, with a number needed to harm of five. For recurrent pneumonia and recurrent fracture, the hazard ratios were significantly increased in the prevalent and inception cohorts (hazard ratios, 2.88 and 2.85 for pneumonia, respectively; 1.77 and 1.57 for fracture, respectively).
"The clinical use of and indications for ICS therapy in COPD should be carefully considered for each individual before initiation of long-term ICS therapy," the authors write.
Several authors disclosed ties to the pharmaceutical industry, and the study was funded by a research grant from Boehringer Ingelheim.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Persistent, New Mucus Plugs Associated With Faster Decline in FEV1 in COPD
WEDNESDAY, May 21, 2025 -- For patients with chronic obstructive pulmonary disease (COPD), persistent and newly formed mucus plugs are associated with a faster decrease in forced...
Mepolizumab Yields Lower Rate of Moderate/Severe Exacerbations in COPD
MONDAY, May 12, 2025 -- For patients with chronic obstructive pulmonary disease (COPD) with a history of exacerbations and a blood eosinophil count of at least 300 cells/µL...
Women Have Higher Risk for COPD Than Men, Regardless of Smoking History
FRIDAY, May 9, 2025 -- Among adults aged 40 years and older, women have an increased risk for chronic obstructive pulmonary disease (COPD), according to a study published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.